15 citations
,
December 2020 in “Pharmacology Research & Perspectives” This review discusses targeting host cell proteases as a novel approach to inhibit SARS-CoV-2 infection, highlighting transcriptional modulation and enzymatic inhibition as promising therapeutic strategies, but it reports no new clinical findings.
4 citations
,
June 2025 in “Medeniyet Medical Journal” This review explores the role of the TMPRSS2 gene in facilitating SARS-CoV-2 infection and its potential as a therapeutic target in COVID-19 and other respiratory infections, highlighting challenges in developing selective inhibitors.
77 citations
,
July 2020 in “European Journal of Clinical Pharmacology” This review explores potential early-stage pharmacologic interventions for COVID-19 by targeting virus entry into host cells, identifying several existing drugs for further investigation, but reports no new clinical results.
228 citations
,
January 2021 in “Journal of Neuroimmune Pharmacology” This review explores possible reasons for why male COVID-19 patients experience more severe symptoms and higher fatality rates than female patients but provides no new clinical results.
34 citations
,
September 2020 in “BMC Endocrine Disorders” This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.